blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3336097

EP3336097 - PREPARATION OF THE NON-CRYSTALLINE FORM OF OBETICHOLIC ACID [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.06.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  17.07.2020
FormerGrant of patent is intended
Status updated on  02.03.2020
FormerExamination is in progress
Status updated on  28.06.2019
FormerRequest for examination was made
Status updated on  04.01.2019
FormerThe application has been published
Status updated on  18.05.2018
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Intercept Pharmaceuticals, Inc.
10 Hudson Yards, 37th Floor
New York, NY 10001 / US
[2018/25]
Inventor(s)01 / STEINER, André
PharmaZell GmbH
Rosenheimer Str. 43
83064 Raubling / DE
02 / WAENERLUND POULSEN, Heidi
FeF Chemicals A/S
Kobenhavnsvej 216
4600 Køge / DK
03 / JOLIBOIS, Emilie
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
04 / REWOLINSKI, Melissa
4760 Eastgate Mall
San Diego, CA 92121 / US
05 / GROSS, Ralf
PharmaZell GmbH
Rosenheimer Str. 43
83064 Raubling / DE
06 / SHARP, Emma
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
07 / DUBAS-FISHER, Fiona
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
08 / EBERLIN, Alex
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
 [2020/34]
Former [2018/25]01 / STEINER, André
PharmaZell GmbH
Rosenheimer Str. 43
83064 Raubling / DE
02 / WAENERLUND POULSEN, Heidi
FeF Chemicals A/S
Kobenhavnsvej 216
DK-4600 Køge / DK
03 / JOLIBOIS, Emilie
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
04 / REWOLINSKI, Melissa
4760 Eastgate Mall
San Diego, CA California 92121 / US
05 / GROSS, Ralf
PharmaZell GmbH
Rosenheimer Str. 43
83064 Raubling / DE
06 / SHARP, Emma
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
07 / DUBAS-FISHER, Fiona
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
08 / EBERLIN, Alex
Pharmorphix Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE / GB
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[N/P]
Former [2018/25]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Application number, filing date17202916.717.06.2013
[2018/25]
Priority number, dateUS201261661531P19.06.2012         Original published format: US 201261661531 P
[2018/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3336097
Date:20.06.2018
Language:EN
[2018/25]
Type: B1 Patent specification 
No.:EP3336097
Date:19.08.2020
Language:EN
[2020/34]
Search report(s)(Supplementary) European search report - dispatched on:EP02.05.2018
ClassificationIPC:C07J9/00, C07J51/00, A61K9/20, // A61K31/575
[2020/12]
CPC:
C07J9/005 (EP,CN,EA,KR,US); A61K9/2054 (EP,CN,EA,KR,US); A61K31/56 (KR);
A61K31/575 (EP,EA,KR,US); A61P1/16 (EP,EA); A61P13/04 (EP);
A61P3/06 (EP); A61P31/14 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07J51/00 (EP,CN,EA,KR,US);
C07J9/00 (EA); C07B2200/13 (EP,EA,KR,US) (-)
Former IPC [2018/25]C07J9/00, C07J51/00, // A61K31/575
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/06]
Former [2018/25]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ZUBEREITUNG DER NICHT-KRISTALLINEN FORM VON OBETICHOLSÄURE[2018/25]
English:PREPARATION OF THE NON-CRYSTALLINE FORM OF OBETICHOLIC ACID[2018/25]
French:PRÉPARATION DE LA FORME NON-CRYSTALLINE D'ACIDE OBETICHOLIQUE[2018/25]
Examination procedure20.12.2018Amendment by applicant (claims and/or description)
20.12.2018Examination requested  [2019/06]
20.12.2018Date on which the examining division has become responsible
02.07.2019Despatch of a communication from the examining division (Time limit: M04)
12.11.2019Reply to a communication from the examining division
03.03.2020Communication of intention to grant the patent
10.07.2020Fee for grant paid
10.07.2020Fee for publishing/printing paid
10.07.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13733181.5  / EP2861613
Divisional application(s)EP20190630.2  / EP3789394
EP21195801.2  / EP3992201
Opposition(s)20.05.2021No opposition filed within time limit [2021/30]
Fees paidRenewal fee
21.11.2017Renewal fee patent year 03
21.11.2017Renewal fee patent year 04
21.11.2017Renewal fee patent year 05
27.06.2018Renewal fee patent year 06
27.06.2019Renewal fee patent year 07
29.06.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.06.2013
AL19.08.2020
CY19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
MK19.08.2020
MT19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
[2024/42]
Former [2024/22]HU17.06.2013
AL19.08.2020
CY19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
MK19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2023/33]HU17.06.2013
AL19.08.2020
CY19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2023/30]AL19.08.2020
CY19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2022/08]AL19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2021/25]AL19.08.2020
EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2021/22]EE19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
RO19.08.2020
RS19.08.2020
SM19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2021/10]HR19.08.2020
LT19.08.2020
LV19.08.2020
RS19.08.2020
BG19.11.2020
GR20.11.2020
IS19.12.2020
Former [2021/07]LT19.08.2020
Documents cited:Search[A]EP1568706  (INTERCEPT PHARMACEUTICALS INC [US]) [A] 1-14 * examples 1-3 *;
 [A]WO2006122977  (ERREGIERRE SPA [IT], et al) [A] 1-14 * example 1 *;
 [A]  - SEPE V ET AL, "Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 55, no. 1, doi:10.1021/JM201004P, ISSN 0022-2623, (20120112), pages 84 - 93, (20111129), XP002711362 [A] 1-14 * page 87, scheme 1 * * page 91, column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1021/jm201004p
 [A]  - GIOIELLO ANTIMO ET AL, "Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3[alpha],7[alpha]-dihydroxy-6[alpha]-ethyl-24-nor-5[beta]-cholan-23-amine", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 19, no. 8, doi:10.1016/J.BMC.2011.03.004, ISSN 0968-0896, (20110415), pages 2650 - 2658, (20110310), XP002711363 [A] 1-14 * page 2652, scheme 1 *

DOI:   http://dx.doi.org/10.1016/J.BMC.2011.03.004
by applicantUS5023252
 US7138390
 WO2006122977
 US2009062526
    - L. BETTARELLO et al., II Farmaco, (20000000), vol. 55, pages 51 - 55
    - HOOFT et al., J. Appl. Cryst., (20080000), vol. 41, pages 96 - 103
    - J. KERC et al., Thermochim. Acta, (19950000), no. 248, pages 81 - 95
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.